All In Biotech

Drug Trial Radar · NCT01293097

Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing PCI

Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention(PCI)

Last checked: Nov 19, 2026Latest source record: Apr 30, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 2,884 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,884

Actual

Start

Jun 2010

Primary completion

Oct 2011

Study completion Oct 2011

Sponsor

Lead sponsor
Peking University First HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 10, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 20 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized, open label, controlled, parallel group study is designed to test whether 2-day high dose atorvastatin administration before PCI and 30-day continuous intensive atorvastatin treatment is superior to usual care, in terms of peri-PCI cardiovascular events, as well as 6-month prognosis. The goal is to set up an optimized protocol for peri-PCI statin treatment in Chinese CHD patients. Safety will also be observed.

Conditions

  • Non-ST Segment Elevation Myocardial Infarction
  • Unstable Angina Pectoris
  • Stable Angina Pectoris

Interventions

  • AtorvastatinDrug

    Atorvastatin 80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care

  • StatinDrug

    Usual care, but statin dose should not be higher than that described in exclusion criteria

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 30-day MACEs after PCITime frame: 30 days after PCI

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Division of Cardiology, Peking University First Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.